论文部分内容阅读
目的 :评价国产头孢哌酮 /舒巴坦治疗细菌性感染的有效性和安全性。方法 :60例感染患者被选入随机对照及开放试验。结果 :随机对照组 4 3例 ,两组痊愈率和有效率分别为 77 2 7% ,71 4 3 %和 95 5 1% ,90 5 %。细菌阳性率为 95 4 5 %和95 2 4 %。细菌清除率为 90 4 8%和 90 0 %。不良反应发生率为 9 0 9%和 9 5 2 %。以上结果经统计学处理均无显著差异 (P>0 0 5 )。开放试验组 17例 ,其痊愈率和有效率分别为 73 3 3 %和 93 3 3 %。细菌阳性率为 94 1%。细菌清除率为 87 5 %。不良反应发生率为 12 0 %。全部临床分离菌株纸片法药敏试验及MIC结果表明头孢哌酮 /舒巴坦明显优于氨苄青霉素 /克拉维酸。结论 :头孢哌酮 /舒巴坦可作为临床上常见致病菌所致中至重度感染的选择用药。
Objective: To evaluate the efficacy and safety of domestic cefoperazone / sulbactam in the treatment of bacterial infections. Methods: Sixty infected patients were enrolled in a randomized controlled trial and an open trial. Results: There were 43 cases in the randomized control group. The cure rate and effective rate of the two groups were 77 2 7%, 71 4 3% and 95 5 1%, 90 5% respectively. The positive rates of bacteria were 95 4 5% and 95 2 4%. Bacterial clearance rates were 90 4 8% and 90 0%. The incidence of adverse reactions was 9 0 9% and 95 2%. The above results were statistically significant (P> 0.05). In the open trial group, 17 cases were cured and their effective rate was 73.3% and 93.3% respectively. The positive rate of bacteria was 94 1%. Bacterial clearance was 87.5%. The incidence of adverse reactions was 120%. All clinical isolates of paper disk susceptibility testing and MIC results show that cefoperazone / sulbactam was significantly superior to ampicillin / clavulanic acid. Conclusion: Cefoperazone / sulbactam can be used as the choice of moderate to severe infections caused by common pathogenic bacteria.